(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.


Figure 1


Fig. 1. Comparison of the effects of aPKC{lambda} kn and of myosin-II inhibitors on the junction development of MTD1-A cells. (A) Myosin inhibitors and aPKC{lambda} kn, a dominant-negative mutant of aPKC{lambda}, block junction development similarly but affect actin reorganization differently. Confluent monolayers of MTD1-A cells transformed by adenovirus vectors encoding β-galactosidase (LacZ) or aPKC{lambda} kn were cultured in LC medium for 40 hours and then subjected to a Ca2+ switch in the presence or absence of the myosin inhibitors blebbistatin (100 µM) or Y27632 (20 µM). The cells were fixed at 6 hours after the Ca2+ switch and stained with an anti-ZO-1 antibody (magenta in merged images) and phalloidin (green in merged images). The images shown are single confocal sections that were selected to demonstrate the ZO-1 staining most clearly. Enlargements of the boxed regions in the merged views are shown at the bottom. For cells overexpressing aPKC{lambda} kn, two typical images are presented, in which the left and right panels show cells exhibiting tightly and loosely bundled circumferential actin cables, respectively (each represents ~40% and ~60% of aPKC{lambda}-kn-overexpressing cells, respectively). White arrowheads, circumferential actin cables; arrows, punctate staining of F-actin on spot-like AJs; yellow arrowheads, radial actin fibers. (B) Schematic presentation of the intermediate state of F-actin organization observed in aPKC{lambda}-kn-overexpressing cells. (C) RNAi knockdown of aPKC isoforms in MTD1-A cells. Subconfluent MTD1-A cells were transfected with the indicated siRNA oligonucleotide duplexes (NS, non-silencing siRNA; {lambda}3, aPKC{lambda} siRNA; {zeta}1, aPKC{zeta} siRNA). Top panels: western blot analyses of total extracts of cells subjected to the indicated RNAi. aPKC{lambda} was specifically detected by an anti-aPKC{iota} (human aPKC{lambda}) antibody, whereas both aPKC isoforms (aPKC{lambda} and aPKC{zeta}) were simultaneously detected by an anti-aPKC antibody (C20) that reacts with both isoforms. GAPDH was used as a loading control. The data for E-cadherin, {alpha}-catenin and β-catenin indicated no significant change in the expression levels of these AJ proteins. Images shown underneath: the indicated cells were immunostained with an anti-aPKC antibody (C20). (D) aPKC knockdown suppresses junction development after a Ca2+ switch, in a similar manner to aPKC{lambda}-kn overexpression. The indicated cells were subjected to a Ca2+ switch as described in A and then immunostained with an anti-ZO-1 antibody (magenta in merged images) and phalloidin (green in merged images). Scale bars: 10 µm.